Your session is about to expire
← Back to Search
Atezolizumab Continuation for Cancer (IMbrella B Trial)
IMbrella B Trial Summary
This trial is for patients who are already receiving atezolizumab and are benefiting from it, and who would not have access to the treatment otherwise. The trial is designed as an extension of a previous study.
IMbrella B Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowIMbrella B Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 3 trial • 1225 Patients • NCT02008227IMbrella B Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am eligible to continue my current atezolizumab therapy or another study drug as per my initial study's protocol.The treatment I am considering is available and approved for my condition in my country.You are currently participating in another clinical trial for a treatment.I am currently benefiting from my atezolizumab-based treatment as assessed by my doctor.I agree to not have unprotected sex or donate sperm.I stopped taking atezolizumab for any reason during or after the previous study.I haven't received any cancer treatment between my last study and this one.I still have serious side effects from a previous study that haven't improved.
- Group 1: Combined Agents with Atezolizumab
- Group 2: Comparator Treatment
- Group 3: Atezolizumab Monotherapy
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the FDA endorsed Atezolizumab for use?
"Our experts at Power have assessed the safety of Atezolizumab to be a 3 due its Phase 4 trial status, signifying that it has been approved for use."
For what medical issues is Atezolizumab typically prescribed?
"Atezolizumab has been found to be a viable treatment for small cell lung cancer, malignant neoplasms, and non-small cell lung carcinoma."
Are there still available slots in this research study for participants?
"As detailed on clinicaltrials.gov, recruitment for this medical trial remains open. It was initially announced on February 28th 2019 and its details were most recently updated November 15th 2022."
Is this an original trial not previously conducted?
"Atezolizumab was initially studied in 2008, backed by Hoffmann-La Roche. After the initial study with 720 participants, Atezolizumab secured Phase 2 approval and is now being tested across 1646 cities in 74 countries through 350 active trials."
Share this study with friends
Copy Link
Messenger